

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Hellyer 1



Section 1.	Identifying Inform	nation				
1. Given Name (First Name) Jessica		2. Surname (Last Name) Hellyer	3. Date 22-August-2018			
4. Are you the corresponding author?		Yes ✓ No	Corresponding Author's Name Heather Wakelee			
5. Manuscript Title Pembrolizumab in patients with thymic carcinoma: a cautionary tale						
6. Manuscript Ider	ntifying Number (if you kr	now it)				
Section 2.	The Work Under Co	onsideration for Public	ation			
any aspect of the s statistical analysis,	stitution <b>at any time</b> rece ubmitted work (including	ive payment or services from but not limited to grants, dat	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,			
Section 3.	Relevant financial	activities outside the s	ubmitted work.			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo						
Section 4.	Intellectual Proper	rty Patents & Copyrig	hts			
Do you have any			oadly relevant to the work? ☐ Yes ✓ No			

Hellyer 2



Section 5. Relationships not covered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Hellyer has nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Hellyer 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

Padda 1



**Identifying Information** 

Section 1.

# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

1. Given Name (First Name) Sukhmani	<ol><li>Surname (Last Name Padda</li></ol>	e)	3. Date 22-August-2018
4. Are you the corresponding author?	☐ Yes 🗸 No	Correspond Heather W	ding Author's Name Vakelee
5. Manuscript Title Pembrolizumab in patients with thym	ic carcinoma: a cautiona	ary tale	
6. Manuscript Identifying Number (if you	know it)		
Section 2. The Work Under (	Consideration for Pu	blication	
			(government, commercial, private foundation, etc.) fo g board, study design, manuscript preparation,
Are there any relevant conflicts of inte	rest? Yes 🗸 N	lo	
Section 3. Relevant financia	l activities outside th	he submitted	work.
of compensation) with entities as desc	ribed in the instructions	s. Use one line fo	ove financial relationships (regardless of amount or each entity; add as many lines as you need by uring the 36 months prior to publication.
Are there any relevant conflicts of inte		lo	
If yes, please fill out the appropriate in	formation below.		
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments
Epicentrx	<b>✓</b>		research funding
Bayer	<b>✓</b>		research funding
Boehringer Ingelheim	<b>✓</b>		research funding
Pfizer			advisory board
AstraZeneca			advisory board
G1 Therapeutic			advisory board
47 Inc.	<b>✓</b>		research funding

Padda 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Padda reports grants from Epicentrx, grants from Bayer, grants from Boehringer Ingelheim, personal fees from Pfizer, personal fees and other from AstraZeneca, personal fees from G1 Therapeutic, grants from 47 Inc., outside the submitted work;.

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Padda 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



**Identifying Information** 

Section 1.

# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

<ol> <li>Given Name (First Name)</li> <li>Heather</li> </ol>	<ol><li>Surname (Last Name)</li><li>Wakelee</li></ol>				3. Date 22-August-2018		
4. Are you the corresponding author?	✓ Yes	No					
5. Manuscript Title Pembrolizumab in patients with thymic	carcinom	a: a cautior	nary tale				
6. Manuscript Identifying Number (if you kr	now it)						
Section 2. The Work Under Co	onsidera	tion for P	ublication				
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not lin		nts, data monitoring			c.) for	
Section 3. Relevant financial	activities	s outside	the submitted	work.			
Place a check in the appropriate boxes in of compensation) with entities as describing the "Add +" box. You should replace there any relevant conflicts of interesting the please fill out the appropriate info	ibed in the port relation est? ✓	e instruction onships tha Yes	ns. Use one line fo	or each er	ntity; add as many lines as you need	d by	
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
BMS	<b>√</b>				Research Funding		
exelixis	<b>✓</b>				Research Funding		
illy	<b>✓</b>				Research Funding		
Pfizer	<b>✓</b>				Research Funding		
Gilead	<b>✓</b>				Research Funding		
Novartis		<b>✓</b>			Honoraria		
AstraZeneca		<b>✓</b>			advisor and honoraria		
Takeda Takeda		<b>✓</b>			consultant (not compensated)		



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Pharmacyclics	<b>✓</b>				Research Funding
Xcovery		<b>✓</b>			consultant
Janssen		<b>✓</b>			consultant
ACEA Biosciences	<b>✓</b>				Research Funding
Daiichi Sankyo, INC		<b>✓</b>			consultant
AstraZeneca/MedImmune	<b>✓</b>				Research Funding
Xcovery	<b>✓</b>				Research Funding
Blueprint		<b>✓</b>			advisor
Celgene	<b>✓</b>				Research Funding
Clovis Oncology	<b>✓</b>				Research Funding
Genetech/Roche	<b>✓</b>	<b>✓</b>			Research Funding and advisor (not compensated)
Arrys Therapuetics	<b>✓</b>				Research Funding
Novartis	<b>✓</b>				Research Funding
Merck	<b>✓</b>	<b>✓</b>			Research Funding and advisor (not compensated)
Helsinn		<b>✓</b>			advisor
Mirati		<b>✓</b>			advisor
Cellworks		<b>✓</b>			advisor

Section 4.	Intellectual Property Patents & Copyrights	
Do you have an	y patents, whether planned, pending or issued, broadly relevant to the work?	<b>√</b> No



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. Thals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

Dr. Wakelee reports grants from BMS, grants from Exelixis, grants from Lilly, grants from Pfizer, grants from Gilead, personal fees from Novartis, personal fees from AstraZeneca, personal fees from Takeda, grants from Pharmacyclics, personal fees from Xcovery, personal fees from Janssen, grants from ACEA Biosciences, personal fees from Daiichi Sankyo, INC, grants from AstraZeneca/MedImmune, grants from Xcovery, personal fees from Blueprint, grants from Celgene, grants from Clovis Oncology, grants and personal fees from Genetech/Roche, grants from Arrys Therapuetics, grants from Novartis, grants and personal fees from Merck, personal fees from Helsinn, personal fees from Mirati, personal fees from Cellworks, outside the

#### **Evaluation and Feedback**

below.

submitted work;.

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.